Effect of MELD-Na score on overall survival of periampullary cancer.

MELD-Na score Pancreatic adenocarcinoma Pancreaticoduodenectomy

Journal

Updates in surgery

ISSN: 2038-3312

Titre abrégé: Updates Surg

Pays: Italy

ID NLM: 101539818

Informations de publication

Date de publication:
07 May 2024

Historique:

received: 07 10 2023

accepted: 10 04 2024

medline: 7 5 2024

pubmed: 7 5 2024

entrez: 6 5 2024

Statut: aheadofprint

Résumé

Periampullary cancers have a short overall survival (OS), and many prognostic factors have been studied for this purpose. They usually present with biliary obstruction, which negatively affects the liver, kidney, immune system, and cardiovascular system. This study aimed to investigate the effect of MELD-Na scores on OS in patients undergoing pancreaticoduodenectomy due to periampullary cancer. Patients who underwent pancreaticoduodenectomy due to periampullary cancer between January 2010 and January 2021 were included in the study. After applying the exclusion criteria, 80 of the 124 patients were included in the study. The demographic, laboratory, and pathologic data of the patients were analyzed retrospectively. Univariate analysis showed that MELD-Na score at admission, age-adjusted Charlson Comorbidity Index, adjuvant treatment, portal vein resection, lymphovascular invasion (LVI), T-stage, and tumor location were significantly associated with OS (p < 0.1). In multivariate analysis, MELD-Na score at admission (HR: 1.051, 95% CI [1.004-1.101]; p = 0.033), adjuvant treatment (HR: 4.717, 95% CI [2.371-9.383]; p < 0.001), LVI (HR: 2.473, 95% CI [1.355-4.515]; p = 0.003), and tumor location (HR: 2.380, 95% CI [1.274-4.445]; p = 0.007) were independent risk factors for OS. MELD-Na score, adjuvant treatment, LVI, and tumor location were independent risk factors for the OS of periampullary cancer. The MELD-Na score may be used to predict OS for patients undergoing pancreaticoduodenectomy due to periampullary cancer.

Identifiants

DOI: 10.1007/s13304-024-01856-w PMID: 38710890

pubmed: 38710890

doi: 10.1007/s13304-024-01856-w

pii: 10.1007/s13304-024-01856-w

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Poruk KEGJ, Wolfgang CL, Cameron JL (2019) Pancreatic and Periampullary Cancer. In: Yeo CJDS, Fleshman JW, Matthews JB, McFadden DW (eds) Shackelford’s Surgery of The Alımentary Tract, 8th edn. Elsevier, Phladelphia, pp 1137–1148

Peters JH, Carey LC (1991) Historical review of pancreaticoduodenectomy. Am J Surg 161:219–225

doi: 10.1016/0002-9610(91)91134-5 pubmed: 1990875

de Jong EJM, van der Geest LG, Besselink MG et al (2022) Treatment and overall survival of four types of non-metastatic periampullary cancer: nationwide population-based cohort study. HPB (Oxford) 24:1433–1442

doi: 10.1016/j.hpb.2022.01.009 pubmed: 35135724

Xia T, Wu X, Mou Y et al (2021) Clinicopathological prognostic factors and chemotherapeutic outcome for two histopathological types of ampulla of vater adenocarcinoma. Front Oncol 11:616108

doi: 10.3389/fonc.2021.616108 pubmed: 33680964 pmcid: 7930557

Helm J, Centeno BA, Coppola D et al (2009) Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer. Cancer 115:4080–4089

doi: 10.1002/cncr.24503 pubmed: 19626671

Mauro E, Garcia-Olveira L, Gadano A (2021) End-stage liver disease: management of hepatorenal syndrome. Liver Int 41(Suppl 1):119–127

doi: 10.1111/liv.14866 pubmed: 34155791

Engin H, Bilir C, Ustundag Y (2013) MELD-sodium score and its prognostic value in malignancy-related ascites of pancreatic and gastric cancer. Support Care Cancer 21:1153–1156

doi: 10.1007/s00520-012-1640-3 pubmed: 23104454

Huo TI, Lin HC, Hsia CY et al (2008) The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis 40:882–889

doi: 10.1016/j.dld.2008.01.015 pubmed: 18339595

Schwarz L, Regimbeau JM, Rebibo L (2020) What are the particularities of pancreatic surgery in the cirrhotic patient? Chirurgia (Bucur) 115:185–190

doi: 10.21614/chirurgia.115.2.185 pubmed: 32369722

Wong VW, Chim AM, Wong GL, Sung JJ, Chan HL (2007) Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. Liver Transpl 13:1228–1235

doi: 10.1002/lt.21222 pubmed: 17763399

Pavlidis ET, Pavlidis TE (2018) Pathophysiological consequences of obstructive jaundice and perioperative management. Hepatobiliary Pancreat Dis Int 17:17–21

doi: 10.1016/j.hbpd.2018.01.008 pubmed: 29428098

Sun XM, Kang P, Tao K (2015) Causes of immune dysfunction in hyperbilirubinemia model rats. Asian Pac J Trop Med 8:382–385

doi: 10.1016/S1995-7645(14)60348-5 pubmed: 26003598

Khan NM, Poduval TB (2011) Immunomodulatory and immunotoxic effects of bilirubin: molecular mechanisms. J Leukoc Biol 90:997–1015

doi: 10.1189/jlb.0211070 pubmed: 21807743

Khurana S, Raufman JP, Pallone TL (2011) Bile acids regulate cardiovascular function. Clin Transl Sci 4:210–218

doi: 10.1111/j.1752-8062.2011.00272.x pubmed: 21707953 pmcid: 3705909

Berardi R, Mocchegiani F, Rinaldi S et al (2020) Hyponatremia is a predictor of clinical outcome for resected biliary tract cancers: a retrospective single-center study. Oncol Ther 8:115–124

doi: 10.1007/s40487-020-00112-6 pubmed: 32700076 pmcid: 7359997

Martinez-Rodenas F, Pereira JA, Jimenez W, Gubern JM, Sitges-Serra A (1998) Circulating bile is the main factor responsible for atrial natriuretic peptide release in experimental obstructive jaundice. Br J Surg 85:480–484

doi: 10.1046/j.1365-2168.1998.00661.x pubmed: 9607527

Gerbes AL (1993) The role of atrial natriuretic peptide (ANP) in chronic liver disease. Pharmacol Ther 58:381–390

doi: 10.1016/0163-7258(93)90028-C pubmed: 8248285

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383

doi: 10.1016/0021-9681(87)90171-8 pubmed: 3558716

Charlson ME, Carrozzino D, Guidi J, Patierno C (2022) Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom 91:8–35

doi: 10.1159/000521288 pubmed: 34991091

Aoyama T, Yamamoto N, Kamiya M et al (2020) The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy. J Cancer Res Ther 16:S116–S121

doi: 10.4103/jcrt.JCRT_440_18 pubmed: 33380664

Takada Y, Kawashima H, Ohno E et al (2022) The impact of the age-adjusted Charlson comorbidity index as a prognostic factor for endoscopic papillectomy in ampullary tumors. J Gastroenterol 57:199–207

doi: 10.1007/s00535-022-01853-z pubmed: 35098349

Robert PE, Leux C, Ouaissi M et al (2014) Predictors of long-term survival following resection for ampullary carcinoma: a large retrospective French multicentric study. Pancreas 43:692–697

doi: 10.1097/MPA.0000000000000112 pubmed: 24713843

Shimizu Y, Ashida R, Sugiura T et al (2022) Prognostic impact of indicators of systemic inflammation and the nutritional status of patients with resected carcinoma of the ampulla of vater: a single-center retrospective study. World J Surg 46:246–258

doi: 10.1007/s00268-021-06346-3 pubmed: 34661701

Zhang S, Cui Y, Zhao X et al (2022) Development and validation of a prognostic nomogram for extrahepatic bile duct adenocarcinoma. Front Oncol 12:950335

doi: 10.3389/fonc.2022.950335 pubmed: 36408181 pmcid: 9668252

Strijker M, Belkouz A, van der Geest LG et al (2019) Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncol 58:1048–1055

doi: 10.1080/0284186X.2019.1590634 pubmed: 30907207

Jun SY, Sung YN, Lee JH, Park KM, Lee YJ, Hong SM (2019) Validation of the eighth american joint committee on cancer staging system for distal bile duct carcinoma. Cancer Res Treat 51:98–111

doi: 10.4143/crt.2017.595 pubmed: 29510611

Vilhordo DW, Gregorio C, Valentini DF Jr, Edelweiss MIA, Uchoa DM, Osvaldt AB (2021) Prognostic factors of long-term survival following radical resection for ampullary carcinoma. J Gastrointest Cancer 52:872–881

doi: 10.1007/s12029-020-00479-9 pubmed: 32808236

Matsui S, Yamamoto Y, Sugiura T et al (2021) The prognostic relevance of the number and location of positive lymph nodes for ampulla of vater carcinoma. World J Surg 45:270–278

doi: 10.1007/s00268-020-05770-1 pubmed: 32909124

Kwon J, Kim K, Chie EK et al (2017) Prognostic relevance of lymph node status for patients with ampullary adenocarcinoma after radical resection followed by adjuvant treatment. Eur J Surg Oncol 43:1690–1696

doi: 10.1016/j.ejso.2017.05.024 pubmed: 28648977

Seppanen H, Juuti A, Mustonen H et al (2017) The results of pancreatic resections and long-term survival for pancreatic ductal adenocarcinoma: a single-institution experience. Scand J Surg 106:54–61

doi: 10.1177/1457496916645963 pubmed: 27130378

Chandrasegaram MD, Chen JW, Price TJ, Zalcberg J, Sjoquist K, Merrett ND (2016) Advances in molecular pathology and treatment of periampullary cancers. Pancreas 45:32–39

doi: 10.1097/MPA.0000000000000385 pubmed: 26348463

Duan Z, Zhang Y, Tang Y, Gao R, Bao J, Liang B (2022) Adjuvant therapy for periampullary carcinoma and the significance of histopathological typing: a systematic review. Transl Oncol 20:101414

doi: 10.1016/j.tranon.2022.101414 pubmed: 35397420 pmcid: 9006738

Nassour I, Hynan LS, Christie A et al (2018) Association of adjuvant therapy with improved survival in ampullary cancer: a national cohort study. J Gastrointest Surg 22:695–702

doi: 10.1007/s11605-017-3624-6 pubmed: 29127604

Acharya A, Markar SR, Sodergren MH et al (2017) Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. Br J Surg 104:814–822

doi: 10.1002/bjs.10563 pubmed: 28518410

Zhou J, Hsu CC, Winter JM et al (2009) Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiother Oncol 92:244–248

doi: 10.1016/j.radonc.2009.05.006 pubmed: 19541379 pmcid: 3700350

Napoli N, Kauffmann EF, Ginesini M et al (2023) Ca 125 is an independent prognostic marker in resected pancreatic cancer of the head of the pancreas. Updates Surg 75:1481–1496

doi: 10.1007/s13304-023-01587-4 pubmed: 37535191 pmcid: 10435596

De Pastena M, Zingaretti CC, Paiella S et al (2024) Impact of extra-ampullary duodenal adenocarcinoma subtypes on surgical and oncological outcomes following pancreaticoduodenectomy. Updates Surg 76:87–95

doi: 10.1007/s13304-023-01688-0 pubmed: 38093152

Skorzewska M, Kurzawa P, Ciszewski T, Pelc Z, Polkowski WP (2022) Controversies in the diagnosis and treatment of periampullary tumours. Surg Oncol 44:101853

doi: 10.1016/j.suronc.2022.101853 pubmed: 36152420